Literature DB >> 3978229

Immune complexes containing factor V in a patient with an acquired neutralizing antibody.

H C Chiu, A K Rao, C Beckett, R W Colman.   

Abstract

An 82-year-old woman presented with extensive hematomas and melena associated with markedly decreased plasma factor V coagulant activity (FV:C). Using a competitive enzyme-linked immunosorbent assay developed in our laboratory, we made serial measurements of factor V antigen (FV:Ag) in plasma and found it to be normal or elevated. The patient's plasma was demonstrated to contain an IgG antibody that could neutralize FV:C in normal plasma. The antibody was of restricted heterogeneity (IgG1, IgG2,kappa). Circulating immune complexes containing antibody to factor V and FV:Ag were demonstrated directly in the plasma by immunoelectrophoresis with polyclonal monospecific antibody and with a monoclonal antibody using an enzyme-linked immunosorbent assay. Presence of neutralizing antibody could be demonstrated in vitro even at times when FV:C was within normal limits by heat inactivation of FV:C. Treatment with plasma and platelet transfusions as well as plasmapheresis induced definite but transient elevation of FV:C. Steroid therapy lowered the neutralizing antibody concentration and produced a rapid and persistent elevation of FV:C during two separate hospitalizations. This report describes a patient in whom levels of FV:Ag have been serially measured, and the presence of circulating immune complexes consisting of factor V and a neutralizing antibody have been directly demonstrated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978229

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Authors:  T L Ortel; M A Quinn-Allen; L A Charles; D Devore-Carter; W H Kane
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

3.  Isolation and study of an acquired inhibitor of human coagulation factor V.

Authors:  M E Nesheim; W L Nichols; T L Cole; J G Houston; R B Schenk; K G Mann; E J Bowie
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.

Authors:  B Tribl; P Knöbl; K Derfler; S Kapiotis; G Aspöck; U Jäger; W Hörl; K Lechner
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.